These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 27003155)

  • 21. Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis.
    Fumagalli C; Rappa A; Casadio C; Betella I; Colombo N; Barberis M; Guerini-Rocco E
    J Clin Pathol; 2020 Mar; 73(3):168-171. PubMed ID: 31537627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer.
    Trujillano D; Weiss ME; Schneider J; Köster J; Papachristos EB; Saviouk V; Zakharkina T; Nahavandi N; Kovacevic L; Rolfs A
    J Mol Diagn; 2015 Mar; 17(2):162-70. PubMed ID: 25556971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.
    Cini G; Mezzavilla M; Della Puppa L; Cupelli E; Fornasin A; D'Elia AV; Dolcetti R; Damante G; Bertok S; Miolo G; Maestro R; de Paoli P; Amoroso A; Viel A
    BMC Med Genet; 2016 Feb; 17():11. PubMed ID: 26852130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The molecular analysis of BRCA1 and BRCA2: Next-generation sequencing supersedes conventional approaches.
    D'Argenio V; Esposito MV; Telese A; Precone V; Starnone F; Nunziato M; Cantiello P; Iorio M; Evangelista E; D'Aiuto M; Calabrese A; Frisso G; D'Aiuto G; Salvatore F
    Clin Chim Acta; 2015 Jun; 446():221-5. PubMed ID: 25896959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
    Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
    Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.
    Walsh CS
    Gynecol Oncol; 2015 May; 137(2):343-50. PubMed ID: 25725131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling.
    Petersen AH; Aagaard MM; Nielsen HR; Steffensen KD; Waldstrøm M; Bojesen A
    Eur J Hum Genet; 2016 Aug; 24(8):1104-11. PubMed ID: 26733283
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Kim DH; Cho CH; Kwon SY; Ryoo NH; Jeon DS; Lee W; Ha JS
    J Gynecol Oncol; 2018 Nov; 29(6):e90. PubMed ID: 30207098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
    Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
    [No Abstract]   [Full Text] [Related]  

  • 31. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
    Dougherty BA; Lai Z; Hodgson DR; Orr MCM; Hawryluk M; Sun J; Yelensky R; Spencer SK; Robertson JD; Ho TW; Fielding A; Ledermann JA; Barrett JC
    Oncotarget; 2017 Jul; 8(27):43653-43661. PubMed ID: 28525389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
    Kim ET; Jeong HE; Yoon HJ; Kim KH; Suh DS
    Taiwan J Obstet Gynecol; 2023 Jan; 62(1):66-70. PubMed ID: 36720553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach.
    Moss HA; Samimi G; Havrilesky LJ; Sherman ME; Myers ER
    Genet Epidemiol; 2018 Feb; 42(1):117-122. PubMed ID: 29193313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of an amplicon-based next-generation sequencing panel for detection of BRCA1 and BRCA2 genetic variants.
    Shin S; Hwang IS; Lee ST; Choi JR
    Breast Cancer Res Treat; 2016 Aug; 158(3):433-40. PubMed ID: 27383479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
    Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
    Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-Generation Sequencing of Tubal Intraepithelial Carcinomas.
    McDaniel AS; Stall JN; Hovelson DH; Cani AK; Liu CJ; Tomlins SA; Cho KR
    JAMA Oncol; 2015 Nov; 1(8):1128-32. PubMed ID: 26181193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
    De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
    Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next-generation sequencing.
    Jones MA; Timms KM; Hatcher S; Cogan ES; Comeaux MS; Perry M; Morris B; Swedlund B; Elks CE; Lao-Sirieix P; Dearden S; Egile C; Brown JS; Harrington EA; Hodgson D; Stern M; Slavin TP; Mancini-DiNardo D
    Genes Chromosomes Cancer; 2023 Oct; 62(10):589-596. PubMed ID: 37222498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.